Haruka Kuriyama Selected Research

Haruka Kuriyama Research Topics

13	Melanoma (Melanoma, Malignant) 01/2024 - 01/2019
6	Neoplasms (Cancer) 01/2023 - 01/2020
1	Uveitis 11/2023
1	Psoriasis (Pustulosis Palmaris et Plantaris) 10/2023
1	Inflammation (Inflammations) 09/2021
1	Disseminated Intravascular Coagulation 06/2020
1	Experimental Melanoma 01/2020
1	Brain Abscess (Abscess, Brain) 01/2019
1	Hemangiosarcoma (Angiosarcoma) 01/2019
1	Colitis 01/2019
1	Skin Diseases (Skin Disease) 08/2014

4	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2024 - 06/2021
4	NivolumabIBA 01/2024 - 01/2019
4	Immune Checkpoint InhibitorsIBA 01/2024 - 01/2020
2	DNA (Deoxyribonucleic Acid)IBA 10/2023 - 06/2021
2	Biomarkers (Surrogate Marker)IBA 06/2021 - 11/2020
2	Proteins (Proteins, Gene)FDA Link 04/2021 - 11/2020
2	Peptides (Polypeptides)IBA 02/2021 - 01/2020
2	AntigensIBA 02/2021 - 01/2020
1	InterferonsIBA 01/2024
1	pembrolizumabIBA 01/2024
1	dabrafenibIBA 01/2024
1	trametinibIBA 01/2024
1	LigandsIBA 10/2023
1	ChemokinesIBA 10/2023
1	Lactic Acid (Lactate)FDA LinkGeneric 09/2021
1	Early Growth Response Protein 1IBA 09/2021
1	Cell-Free Nucleic AcidsIBA 06/2021
1	Interleukin-15 Receptor alpha SubunitIBA 05/2021
1	Interleukin-15 (Interleukin 15)IBA 05/2021
1	Interferon-betaIBA 05/2021
1	Nucleosomes (Nucleosome)IBA 04/2021
1	CytokinesIBA 02/2021
1	EpitopesIBA 02/2021
1	Small Interfering RNA (siRNA)IBA 11/2020
1	IpilimumabIBA 06/2020
1	OvalbuminIBA 01/2020
1	MicroRNAs (MicroRNA)IBA 01/2020
1	OX40 LigandIBA 01/2020
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2019
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2019
1	cadherin 5IBA 08/2014

7	Therapeutics 01/2024 - 01/2019
3	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2023 - 02/2021
3	Immunotherapy 01/2023 - 01/2020
1	Aftercare (After-Treatment) 02/2021
1	Injections 02/2021
1	Radiotherapy 01/2019